{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-028670","form_type":"8-K","ticker":"EVFM","cik":"0001618835","company_name":"Evofem Biosciences, Inc.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.580164+00:00","generated_at":"2026-06-11T11:19:24.805050+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Evofem Q2 net product sales fall 59% to $2.5M; reduces operating expenses 68%","bullets":["Net product sales $2.5M, down 59% YoY; $1.6M in product returns of short-dated shelf life impacted revenue.","Total operating expenses decreased 68% to $9.8M; selling & marketing down 82% to $2.2M.","Net loss improved to $8.6M ($5.43/share) from $124.1M loss ($580.48/share) in prior year Q2.","Cash at June 30, 2023: $0.6M, down from $4.8M at Dec 31, 2022; raised $1.0M in July and $0.5M in August via convertible notes.","Filed Series E-1 Preferred Stock; investors exchanged $1.8M notes for 1,800 shares convertible at $0.40 per share."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-028670","json":"https://secwatch.observer/filing/0001493152-23-028670.json","markdown":"https://secwatch.observer/filing/0001493152-23-028670.md","text":"https://secwatch.observer/filing/0001493152-23-028670.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223028670/0001493152-23-028670-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223028670/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T11:19:24.805050+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ddb61ec117849633169bc9d8a0efb4b457ae5239","claim":"Evofem Biosciences, Inc. reported the three and six months ended June 30, 2023 results: revenue $2.5 million, net income $8.6 million, EPS $(5.43) per share. Guidance reaffirmed.","evidence_excerpt":"and we remain on track to deliver our third consecutive year of Phexxi net sales growth.” Financial Results For the three months ended June 30, 2023, net product sales were $2.5 million compared to $6.0 million in the prior year period. The 59% decrease was primarily due to lower Phexxi ® (lactic acid, citric acid and potassium bitartrate) ex-factory unit","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223028670/0001493152-23-028670-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and six months ended June 30, 2023"},{"label":"Revenue","value":"$2.5 million"},{"label":"Net income","value":"$8.6 million"},{"label":"EPS","value":"$(5.43) per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}